Pharmaceuticals giant Breckenridges has pulled its entire online pharmacy business from its website after receiving complaints that it was selling a “apellism” drug.
The pharmacy’s news site said the withdrawal is due to a “recent review” by a pharmaceutical watchdog.
Breckenreich announced on Wednesday that it had decided to withdraw the drug, a new anti-infective drug, from its pharmacy services.
“We are a small company that has been selling our online pharmacy service for many years,” the company said.
In addition to this, we will be revoking access to our online service and we will continue to monitor the situation closely and take any appropriate action to protect the integrity of our customers.””
The withdrawal of the service is due solely to this review, which we believe to be warranted.”
In addition to this, we will be revoking access to our online service and we will continue to monitor the situation closely and take any appropriate action to protect the integrity of our customers.
“The apellist is a pharmaceutical medication that contains a chemical compound called apellifene.
It is believed to work by disrupting the immune system, preventing harmful bacteria from multiplying and preventing infection.
The drug has been widely used to treat rheumatoid arthritis, multiple sclerosis, and other conditions.
It’s very concerning that companies are taking this step in response to consumer concerns, but this is a clear example of what happens when a company fails to respond to legitimate concerns.”””
This is the third time we’ve seen this happening,” David Fussell, CEO of the Better Business Bureau, said on Wednesday.
“It’s very concerning that companies are taking this step in response to consumer concerns, but this is a clear example of what happens when a company fails to respond to legitimate concerns.”
“If the FTC can’t do their job in the marketplace, then what can they do?”
Breckens Pharmaceuticals has not commented on the decision to withdraw its online pharmacy, but the company previously said it would not remove the drug from its marketplace.
Brekkens said it is “extremely disappointed” with the decision and would be reviewing its options.
“This action reflects our view that the FDA’s review of Breckens pharmaceuticals has been inadequate and incomplete,” the pharmacy said in a statement.
“As a result, we have withdrawn our online site from Breck’s retail pharmacy and will continue the sale of Brekks drug, Apellis, through our retail pharmacy services.”
The pharmaceutical giant said it had withdrawn its pharmacy service from the internet.
Brektecs said it has not received a complaint from any customers about the drug and that it has no plans to resume selling it.
Breketecs, the biggest pharmacy chain in the US and the third-largest pharmacy chain, said it will continue its online service.
Brekhtric said it also had withdrawn from the online pharmacy market.
“While we continue to receive positive feedback from our customers, we are confident in our ability to continue to sell our pharmacy through our local brick-and-mortar locations, and will review our options in the coming weeks,” the drug maker said in an emailed statement.
“We will continue working closely with our legal counsel to ensure we can continue our mission of serving the best customers in the pharmacy community.”
The FDA said it does not know when the withdrawal of Brekbecs pharmacy would occur.